Tempus AI's 10% stock dip reveals a buying opportunity as Q2 estimates are poised to exceed expectations, fueled by strong deals and an attractive valuation. Read the full analysis here.

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate ...

July 7 – With a 90-day negotiating period on country-specific US tariffs is set to expire on July 9, Trump enacts a multitude ...

Looking for sleep well at night stocks? Read about three stocks that could deliver strong return potential over the next five ...

Novo Nordisk promoted Maziar Mike Doustdar to president and CEO, effective August 7. The Food and Drug Administration tapped newly appointed George Tidmarsh as acting Center for Biologics Evaluation ...

Pharmaceutical stocks are some of the biggest in the FTSE 100. The sector is threatened by tariffs, but some have posted encouraging results regardless.

PainChek, EMVision and Clever Culture Systems are among ASX health companies reporting quarterly results today.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...

Parnassus Investments, an investment management firm, released its “Parnassus Value Equity Fund” second-quarter 2025 investor ...

AstraZeneca PLC AZN has struck a deal to buy a portfolio of gene therapies from Pfizer Inc. PFE for up to $1 billion, the biopharma company announced Friday. The deal, expected to close in the ...

Two diabetes drugs could become more affordable for Maryland residents, following a study by the Prescription Drug ...